{"denoms":[{"counts":[{"groupId":"BG000","value":"436"},{"groupId":"BG001","value":"430"},{"groupId":"BG002","value":"866"}],"units":"Participants"}],"groups":[{"description":"Participants received T-DXd 5.4 mg/kg via IV infusion every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"BG000","title":"T-DXd"},{"description":"Participants received Investigator's choice single-agent chemotherapy (capecitabine 1000 or 1250 mg/m\\^2 orally twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles, paclitaxel 80 mg/m\\^2 via IV infusion qw in 3-week cycles or nab-paclitaxel 100 mg/m\\^2 via IV infusion qw for 3 weeks followed by 1-week rest period in 4-week cycles) until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"BG001","title":"Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.46","value":"58.2"},{"groupId":"BG001","spread":"10.92","value":"58.2"},{"groupId":"BG002","spread":"11.19","value":"58.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"436"},{"groupId":"BG001","value":"429"},{"groupId":"BG002","value":"865"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"7"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"151"},{"groupId":"BG002","value":"305"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"231"},{"groupId":"BG001","value":"230"},{"groupId":"BG002","value":"461"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"19"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"73"}],"title":"Not reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"60"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"397"},{"groupId":"BG001","value":"387"},{"groupId":"BG002","value":"784"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"22"}],"title":"Missing"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"The Intent-to-treat (ITT) population included all randomized participants."}